Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Memorial Sloan Kettering Cancer Center · Seoul National University Hospital · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
539
total citations
- FWCI
- 32.40
- Percentile
- 100%
- References
- 41
Citations per year
Authors
25- JBJosé BaselgaCorresponding
Memorial Sloan Kettering Cancer Center
- SISeock‐Ah Im
Seoul National University Hospital
- HIHiroji Iwata
Aichi Cancer Center
- JCJavier Cortés
Instituto Cajal, Instituto Oncológico Dr. Rosell, Hospital Quirónsalud Barcelona, Vall d'Hebron Institute of Oncology
- MDMichele De Laurentiis
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Topics & keywords
Topics
Keywords
- Fulvestrant
- Medicine
- Breast cancer
- Placebo
- Internal medicine
- Metastatic breast cancer
- Oncology
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.